echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > Phase 3 clinical studies have confirmed that the gonadotropin-releasing hormone (GnRH) receptor antagonist Relugolix significantly reduces pain in women with endometriosis

    Phase 3 clinical studies have confirmed that the gonadotropin-releasing hormone (GnRH) receptor antagonist Relugolix significantly reduces pain in women with endometriosis

    • Last Update: 2020-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Myovant Sciences announced that a triennial relugolix combination therapy (Relugolix 40 mg of estradiol 1.0 mg, acetate ketone 0.5 mg) treats pain in women with endometriosis, a phase III study of ENDoscosis 2 reached the primary therapeutic endpoint and six secondary endpointsAnd Relugolix combination therapy is well toleratedRelugolix is a daily oral gonadotropin release hormone (GnRH) receptor antagonist that reduces the production of ovarian lymgenetics, which stimulates the growth of uterine fibroids and endometriosisin spirit 2 results analysis, 75.2% of women who received relugolix combination therapy achieved clinically meaningful improvements in menstruation, compared with 30.4% in the placebo group (p 0.0001)For non-menstrual pelvic pain, 66.0% of women with relugolix combination therapy achieved a meaningful clinical improvement, with a placebo group of 42.6% (p .0001)On average, women who received relugolix combined treatment for relugolix had a 75.1 percent reduction in pain from 7.2 (severe pain) to 1.7 (mild pain), based on a 11-point (0-10) digital score scaleMyovant also announced that in another clinical study, relugolix combined therapy achieved 100% ovulation inhibition in 67 healthy women over an 84-day treatment period, according to the Hoogland-Skouby Assessment ScaleIn addition, 100 per cent of women who have stopped ovulation or menstruation after discontinuation have an average ovulation time of 23.5 daysendometriosis is an inflammatory disease of estrogen dependencePain caused by endometriosis, initial treatment options include hormonal contraceptives and over-the-counter painkillersIn more severe cases, GnRH agonists can be used for short-term treatmentNearly 200 million women worldwide are affected by the disease
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.